{"id":"b5f8755e-271e-5907-8b46-5195f8dce987","stable_key":"ca8e9e6a-6953-51ec-b712-2b06398a416d:ra-complement-lysis","predicate":"decreases_in_recorded_comparison","statement":"RA inhibited classical- and alternative-pathway hemolysis at IC50 values of 180 and 160 micromolar.","claim_class":"observational","status":"source_recorded","evidence_grade":"ungraded","direction":"negative","is_public":true,"mechanism_event_id":"2398702d-e3b8-5534-9228-bdb02228f519","mechanism_event_label":"RA inhibited classical- and alternative-pathway hemolysis at IC50 values of 180 and 160 micromolar.","subject":{"id":"6072a4ae-d563-5466-a1b2-6d280255d346","slug":"rosmarinic-acid","display_name":"Rosmarinic acid","entity_type_key":"small_molecule"},"object":{"id":"2f18a4e3-a997-5f39-ba0a-f2ea2ed8fca2","slug":"human-complement-hemolysis","display_name":"Human-serum complement-mediated hemolysis","entity_type_key":"cellular_process"},"evidence_count":1,"mechanism_event":{"id":"2398702d-e3b8-5534-9228-bdb02228f519","stable_key":"ca8e9e6a-6953-51ec-b712-2b06398a416d:ra-complement-lysis-event","event_type":"experimental_observation","label":"RA inhibited classical- and alternative-pathway hemolysis at IC50 values of 180 and 160 micromolar.","description":"### ra-complement-lysis\n\nRA inhibited classical- and alternative-pathway hemolysis at IC50 values of 180 and 160 micromolar.\n\nModel and exposure: Human serum hemolytic assays.\nLimitations: Limited to the recorded preparation, model, exposure and endpoint. Does not establish a human dietary deficiency, clinical benefit or unique molecular mediation.\nReference: Inhibition of complement by covalent attachment of rosmarinic acid to activated C3b. | 1999 | https://pubmed.ncbi.nlm.nih.gov/10353266/ | https://doi.org/10.1016/s0006-2952(99)00044-1 | Access: Indexed primary abstract/metadata only; unextracted doses, figures and methods remain unknown.","status":"provisional","compartment":null,"participants":[{"entity":{"id":"6072a4ae-d563-5466-a1b2-6d280255d346","slug":"rosmarinic-acid","display_name":"Rosmarinic acid","entity_type_key":"small_molecule"},"role":"tested factor","stoichiometry":null,"state_label":"RA","sequence_order":0,"notes":""},{"entity":{"id":"2f18a4e3-a997-5f39-ba0a-f2ea2ed8fca2","slug":"human-complement-hemolysis","display_name":"Human-serum complement-mediated hemolysis","entity_type_key":"cellular_process"},"role":"measured outcome","stoichiometry":null,"state_label":"decrease","sequence_order":1,"notes":""},{"entity":{"id":"4e01b8db-55f6-5211-9e66-2b243cc3f2f0","slug":"human-c3b","display_name":"Human complement fragment C3b","entity_type_key":"protein_state"},"role":"attachment pathway component","stoichiometry":null,"state_label":"","sequence_order":2,"notes":""}]},"contexts":[{"dimension":"evidence_access","value_text":"Indexed primary abstract/metadata only; unextracted doses, figures and methods remain unknown.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"experimental_contrast","value_text":"{\"intervention\": \"RA\", \"comparator\": \"No RA\", \"endpoint\": \"RA inhibited classical- and alternative-pathway hemolysis at IC50 values of 180 and 160 micromolar.\", \"effect_direction\": \"decrease\", \"combination\": \"single\", \"conditions\": []}","comparator":null,"unit":null,"notes":"Explicit extracted experimental comparison; recorded from source.","entity":null},{"dimension":"experimental_model","value_text":"Human serum hemolytic assays.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"interpretation_status","value_text":"Recorded from source with stated access limits; ungraded, not independent replication.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"limitations","value_text":"Limited to the recorded preparation, model, exposure and endpoint. Does not establish a human dietary deficiency, clinical benefit or unique molecular mediation.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"nutrient_topic","value_text":"Rosmarinic acid collection; exact intervention and molecular form govern interpretation.","comparator":null,"unit":null,"notes":"","entity":{"slug":"rosmarinic-acid","display_name":"Rosmarinic acid","entity_type_key":"small_molecule"}},{"dimension":"plain_language","value_text":"RA inhibited classical- and alternative-pathway hemolysis at IC50 values of 180 and 160 micromolar.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"primary_references","value_text":"Inhibition of complement by covalent attachment of rosmarinic acid to activated C3b. | https://pubmed.ncbi.nlm.nih.gov/10353266/ | https://doi.org/10.1016/s0006-2952(99)00044-1","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"source_locator","value_text":"Reviewed reference ra-complement-lysis; ","comparator":null,"unit":null,"notes":"","entity":null}],"evidence":[{"id":"02ed571f-5d0a-55d8-84e5-59c604d125df","evidence_kind":"source_excerpt","locator":"Lines 237-243","start_line":237,"end_line":243,"excerpt":"### ra-complement-lysis\n\nRA inhibited classical- and alternative-pathway hemolysis at IC50 values of 180 and 160 micromolar.\n\nModel and exposure: Human serum hemolytic assays.\nLimitations: Limited to the recorded preparation, model, exposure and endpoint. Does not establish a human dietary deficiency, clinical benefit or unique molecular mediation.\nReference: Inhibition of complement by covalent attachment of rosmarinic acid to activated C3b. | 1999 | https://pubmed.ncbi.nlm.nih.gov/10353266/ | https://doi.org/10.1016/s0006-2952(99)00044-1 | Access: Indexed primary abstract/metadata only; unextracted doses, figures and methods remain unknown.","model_system":"Human serum hemolytic assays.","directness":"reported_statement","verification_status":"source_recorded","notes":"Original paraphrase in the retained reviewed reference, not a verbatim primary-paper quotation. Access level is explicit.","relationship":"supports","weight":1.0,"link_notes":"","source":{"id":"606cff22-a6ed-59cd-a84d-87f44c59dc25","stable_key":"import-ca8e9e6a-6953-51ec-b712-2b06398a416d","title":"Rosmarinic acid: detailed mechanisms of action (reviewed 10 October 2026)","document_type":"imported_text","citation_label":"AI-assisted original curation of primary studies; claim-local access and experimental limitations stated. Includes original-draft correction history. No independent replication claimed.","file_path":"","sha256":"684b4eab1dc2c0057f679109770af0de9340af5cd933377b590298cf8a752956","revision_id":"4028d9c5-fb17-54c5-b72c-c6d21678a832","review_status":"source_recorded","notes":""}}],"relations":[],"conflicts":[],"corrections":[],"research":null}